Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Pemetrexed and Carboplatin in Advanced NSCLC
NCT03164694Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- May 2017
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start May 2017; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03164694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164694.